RecruitingNCT06823960

Study to Assess Effectiveness and Safety of Zanubrutinib for Patients With Marginal Zone Lymphoma Treated in Italy Under the Named Patient Program (NPP)

An Italian Multicenter Retrospective Observational Study to Assess Effectiveness and Safety of Zanubrutinib for Patients With Marginal Zone Lymphoma Treated in Italy Under the Named Patient Program (NPP)

Sponsor

IRCCS Azienda Ospedaliero-Universitaria di Bologna

Enrollment

59 participants

Start Date

Dec 9, 2024

Study Type

OBSERVATIONAL

Conditions

Marginal Zone Lymphoma (MZL)

Summary

Observational, non-interventional, retrospective, multicentre study focusing on efficacy and safety of zanubrutinib in daily clinical practice in patients with relapsed/refractory (R/R) marginal zone lymphoma.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is looking at how well zanubrutinib (a targeted therapy drug) works in real-world patients with B-cell malignancies (blood cancers affecting B lymphocytes), outside of the controlled conditions of a clinical trial. **You may be eligible if...** - You are 18 or older - You have a B-cell malignancy such as chronic lymphocytic leukemia (CLL), mantle cell lymphoma, or Waldenström macroglobulinemia - Your doctor has prescribed or is considering zanubrutinib for your condition - You have received at least one prior therapy **You may NOT be eligible if...** - You have not yet tried any treatment for your condition - You have serious active infections - You have major bleeding disorders - You are pregnant or breastfeeding - You are already enrolled in another interventional clinical trial Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Locations(15)

AOU SS Antonio e Biagio e Cesare Arrigo

Alessandria, Alessandria, Italy

IRCCS-AOU di Bologna

Bologna, Bologna, Italy

P.O. Garibaldi-Nesima_UOC Ematologia

Catania, Catania, Italy

AO di Cosenza, P.O. "Annunziata" - UOC di Ematologia

Cosenza, Cosenza, Italy

AOU di Ferrara_ UO di Ematologia - Dipartimento di Oncologia e Medicine Specialistiche

Ferrara, Ferrara, Italy

Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" - IRST IRCCS

Meldola, Forlì Cesena, Italy

Istituto Clinico Humanitas IRCCS - UO Ematologia

Milan, Milano, Italy

ASST Grande Ospedale Metropolitano Niguarda _ UOC Ematologia

Milan, MIlano, Italy

IOV - Istituto Oncologico Veneto - IRCCS _UOC Oncologia1

Padova, Padova, Italy

Ospedali Riuniti Villa Sofia - Cervello _ UO di Ematologia ad Indirizzo Oncologico

Palermo, Palermo, Italy

Ospedale Santa Maria delle Croci- OU Ematologia di Ravenna

Ravenna, Ravenna, Italy

Fondazione PTV Policlinico Tor Vergata- U.O.C. Patologie Linfoproliferative

Roma, Roma, Italy

AOU Città della Salute e della Scienza, "Le Molinette" - Divisione di Ematologia

Torino, Torino, Italy

Ospedale Ca' Foncello, Azienda ULSS n. 2 Marca trevigiana - UOC Ematologia Dipartimento di Medicina

Treviso, Treviso, Italy

Azienda sanitaria universitaria Giuliano Isontina (ASU GI) - Ospedale Maggiore- SC (UCO) Ematologia

Trieste, Trieste, Italy

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06823960

Related Trials

Orelabrutinib Combined With Rituximab ± Lenalidomide in Response-Adapted Stratified Therapy for Untreated MZL

NCT074483241 location

This is a Phase 1 Study to Evaluate the Safety of LTZ-301 in Patients With Non-Hodgkin Lymphoma

NCT071219465 locations